MedTrace Logo

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

NCT02185820 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2023-07-03

No results posted yet for this study

Summary

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations in relapsed and/or refractory Multiple Myeloma (MM) patients.

Conditions

Interventions

DRUG

Carfilzomib

DRUG

Pomalidomide

DRUG

Dexamethasone

Sponsors & Collaborators

  • University of Turin, Italy

    collaborator OTHER

  • European Myeloma Network B.V.

    lead NETWORK

Principal Investigators

  • Sara Bringhen, MD · A.O.U. Città della Salute e della Scienza

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-07-31
Completion
2023-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02185820 on ClinicalTrials.gov